Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment

Imagem de Miniatura
Arquivos
art_BUENO_Cabergoline_and_prolactinomas_lack_of_association_between_DRD2_2017.PDF (363.54 KB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
Citação
PITUITARY, v.20, n.3, p.295-300, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB). Objective To assess the influence of DRD2 polymorphisms in responsiveness of CAB treatment in patients with prolactinoma. Study design and patients Cross-sectional retrospective case-control study analyzing the frequency of five DRD2 polymorphisms in 148 patients with prolactinoma and 349 healthy subjects. The association of genetic variants and clinical characteristics with CAB responsiveness was performed in 118 patients (mean age at diagnosis 29 years; range 11-61 years) with hormonal evaluation. Patients with prolactin (PRL) normalization were considered as responders. Results No association in genotypes and allele proportions was found comparing patients and controls. On pharmacogenetic study, 118 patients on CAB were included and 20% were non-responders. No association was found between clinical characteristics (gender, age, PRL level and tumor size at diagnosis) and polymorphisms of DRD2 with CAB responsiveness. Otherwise, there was association between polymorphisms rs1076560 (allele A) and rs1800497 (allele T) and the presence of macroadenomas. Conclusion No correlation was found between DRD2 polymorphisms and CAB responsiveness in patients with prolactinoma. More data are necessary in order to assess the influence of DRD2 genotyping on DA treatment response.
Palavras-chave
Polymorphism, DRD2, Prolactinoma, Dopamine agonist, Cabergoline
URI
https://observatorio.fm.usp.br/handle/OPI/20241
Referências
  1. BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
  2. Bertolino A, 2009, BRAIN, V132, P417, DOI 10.1093/brain/awn248
  3. Caccavelli L, 1996, J NEUROENDOCRINOL, V8, P737, DOI 10.1046/j.1365-2826.1996.04902.x
  4. CACCAVELLI L, 1994, NEUROENDOCRINOLOGY, V60, P314, DOI 10.1159/000126764
  5. Colao A, 1997, J CLIN ENDOCR METAB, V82, P3574, DOI 10.1210/jc.82.11.3574
  6. Colao A, 2003, EUR J ENDOCRINOL, V148, P325, DOI 10.1530/eje.0.1480325
  7. Colao A, 2000, J CLIN ENDOCR METAB, V85, P2247, DOI 10.1210/jc.85.6.2247
  8. Delgrange E, 2006, CLIN ENDOCRINOL, V64, P456, DOI 10.1111/j.1365-2265.2006.02493.x
  9. Delgrange E, 1997, J CLIN ENDOCR METAB, V82, P2102, DOI 10.1210/jc.82.7.2102
  10. Delgrange E, 2015, EUR J ENDOCRINOL, V172, P791, DOI 10.1530/EJE-14-0990
  11. Delgrange E, 2009, EUR J ENDOCRINOL, V160, P747, DOI 10.1530/EJE-09-0012
  12. Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
  13. Eisenstein SA, 2016, SYNAPSE, V70, P418, DOI 10.1002/syn.21916
  14. Filopanti M, 2008, PHARMACOGENOMICS J, V8, P357, DOI 10.1038/tpj.2008.1
  15. Hansen KA, 2005, FERTIL STERIL, V84, P711, DOI 10.1016/j.fertnstert.2005.03.040
  16. Hardy J, 1973, INT C SERIES, V303, P179
  17. Heinze G, 2006, STAT MED, V25, P4216, DOI 10.1002/sim.2687
  18. Hirvonen M, 2004, MOL PSYCHIATR, V9, P1060, DOI 10.1038/sj.mp.4001561
  19. Hirvonen MM, 2009, SYNAPSE, V63, P907, DOI 10.1002/syn.20672
  20. Ilhan M, 2015, ANN ENDOCRINOL-PARIS, V76, P614, DOI 10.1016/j.ando.2015.08.005
  21. Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532
  22. Jonsson EG, 1999, SCHIZOPHR RES, V40, P31, DOI 10.1016/S0920-9964(99)00033-X
  23. MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
  24. Molitch Mark E, 2005, Pituitary, V8, P43, DOI 10.1007/s11102-005-5085-2
  25. Moura Ronald Rodrigues de, 2015, Am J Hum Biol, V27, P674, DOI 10.1002/ajhb.22714
  26. NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648
  27. Passos VQ, 2009, NEUROENDOCRINOLOGY, V89, P163, DOI 10.1159/000156116
  28. Peculis R, 2016, EUR J ENDOCRINOL, V175, P145, DOI 10.1530/EJE-15-0879
  29. PELLEGRINI I, 1989, J CLIN ENDOCR METAB, V69, P500
  30. Pena SDJ, 2009, BRAZ J MED BIOL RES, V42, P870, DOI 10.1590/S0100-879X2009005000026
  31. Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
  32. Peverelli E, 2012, J CLIN ENDOCR METAB, V97, P967, DOI 10.1210/jc.2011-2902
  33. Pohjalainen T, 1998, MOL PSYCHIATR, V3, P256, DOI 10.1038/sj.mp.4000350
  34. Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758
  35. Schaid DJ, 1999, AM J EPIDEMIOL, V149, P706
  36. Slatkin M, 2008, NAT REV GENET, V9, P477, DOI 10.1038/nrg2361
  37. Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006
  38. Verhelst J, 1999, J CLIN ENDOCR METAB, V84, P2518, DOI 10.1210/jc.84.7.2518
  39. Zada G, 2011, J NEUROSURG, V114, P336, DOI 10.3171/2010.8.JNS10290
  40. Zhang JP, 2010, AM J PSYCHIAT, V167, P763, DOI 10.1176/appi.ajp.2009.09040598
  41. Zhang Y, 2007, P NATL ACAD SCI USA, V104, P20552, DOI 10.1073/pnas.0707106104

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/25